Latest News

  • PARIS, France and CAMBRIDGE, MA, USA  – Sanofi and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically: Sanofi will obtain global development and commercialization rights...
  • VANCOUVER, British Columbia – Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, provided key accomplishments from the past year and announced priorities for 2018. “2017 was a great year for Zymeworks and we are poised to achieve a number of important corporate milestones in 2018,” said Ali Tehrani,...
  • Alzheimer’s disease is a devastating brain illness that affects an estimated 47 million people worldwide. It is the most common cause of dementia in the Western world. Despite this, there are currently no treatments that are effective in curing Alzheimer’s disease or preventing its relentless progression. Alzheimer’s disease is caused...

Videos

Rare disease spotlight

Twitter

CheckOrphan Web Development Team https://checkorphan.wordpress.com/2020/02/06/checkorphan-web-development-team/

Have you already checked #CheckOrphan? Learn about #RareDiseases, their #symptoms and #treatments at http://5.102.147.165/diseases

My week on Twitter 🎉: 2 Mentions, 13 Likes, 2 Retweets, 105 Retweet Reach. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=64bb720613b5a38dd07f5be4

Learn more about #RareDiseases and #OrphanDrugs on #CheckOrphan. Join our #FreeNewsletter at http://5.102.147.165/news

Load More...